Sarepta CEO on what's next after expanded muscular dystrophy drug approval

Douglas Ingram, Sarepta CEO, joins 'Fast Money' to talk FDA approval of Elevidys and its impact on the company's stock.

Related Posts

Companies will hire more as a result of generative AI, ...

admin Nov 8, 2024  0  3

Roblox CEO David Baszucki on new earning opportunities ...

admin Sep 7, 2024  0  7

Shift4 CEO on earnings, state of the consumer and crypto

admin Nov 13, 2024  0  3

Comments

Name

Email

Comment

Post Comment